Journal Article
Corrections
Background: Maintaining target glycosylated hemoglobin (A1C) levels (<7.0%) in patients with type 2 diabetes mellitus (DM) reduces the riskof late DM-associated complications. Previously reported results of a 9-month, uncontrolled observational study (N = 12,216) found that the
addition of insulin glargine, a basal insulin analogue, to existing oral antidiabetic drug (OAD) therapy was associated with reductions in A1C
to target levels.
Previous Journal Article in this issue:
All articles have been reviewed by members of our Editorial Board or independent referees.
You need Adobe Acrobat Reader installed on your computer to read the PDF version of these articles. If you don't have Acrobat Reader, click here to download it free.
